Associazione Nazionale Medici Cardiologi Ospedalieri

www.anmco.it

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
PRIMARY RESULTS FROM APOLLO-B, A PHASE 3 STUDY OF PATISIRAN IN PATIENTS WITH TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH CARDIOMYOPATHY
Anno:
2023
Introduction: Transthyretin-mediated (ATTR) amyloidosis is a progressive, multisystem, fatal disease. Patisiran, an IV RNAi therapeutic, is approved for the treatment of hereditary ATTR amyloidosis with polyneuropathy. The safety and efficacy of patisiran in patients with wild-type or hereditary ATTR amyloidosis with cardiomyopathy (CM) is being investigated in the ongoing…
Leggi di più
EXPLORATORY ANALYSES FROM APOLLO-B, A PHASE 3 STUDY OF PATISIRAN IN PATIENTS WITH ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY
Anno:
2023
Introduction:Transthyretin-mediated (ATTR) amyloidosis is a progressive and fatal disease. Patients with hereditary or wild-type ATTR amyloidosis frequently develop cardiomyopathy (CM). Patisiran, an IV RNAi therapeutic that inhibits synthesis of wt and variant TTR, is approved for the treatment of hATTR amyloidosis with polyneuropathy. Methods:In APOLLO-B, patients were 18–85 yrs…
Leggi di più
Terapia combinata in un paziente con AMILOIDOSI da TTRv
Anno:
2023
Uomo di 73 anni. Ha un fratello con una patologia cardiaca non meglio precisata, tre figli, tutti in buona salute. Ex fumatore, Ipertensione arteriosa, sindrome del tunnel carpale bilaterale da diversi anni. Terapia praticata: zofenopril 7,5 mg 1 cp/die. Ad Agosto 2019 ricovero per scompenso cardiaco acuto. All’ ECOC…
Leggi di più

A.N.M.C.O. – Via La Marmora 36, 50121 Firenze (Italy) – Partita I.V.A. 05469530488 – Codice Fiscale 01301130488 – Privacy
www.anmco.it | segreteria@anmco.it

Seguici su

Facebook Twitter Youtube Linkedin Instagram Telegram